img

Global Human Immune Globulin Intravenous Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Human Immune Globulin Intravenous Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Immune globulin (Ig) short-term protection against hepatitis A and measles
The global Human Immune Globulin Intravenous market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Human Immune Globulin Intravenous is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Human Immune Globulin Intravenous is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Human Immune Globulin Intravenous is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Human Immune Globulin Intravenous include Takeda, Grifols, CSL, Octapharma, Biotest, Kedrion, Hualan Bio, CNBG and Shanghai RAAS, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Human Immune Globulin Intravenous, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Human Immune Globulin Intravenous by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Human Immune Globulin Intravenous market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Human Immune Globulin Intravenous market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
By Type
IVIg Liquid
IVIg Powder
By Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Sales by Region
North America
the United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
UK
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Human Immune Globulin Intravenous in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Human Immune Globulin Intravenous manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Immune Globulin Intravenous sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Human Immune Globulin Intravenous Definition
1.2 Market by Type
1.2.1 Global Human Immune Globulin Intravenous Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 IVIg Liquid
1.2.3 IVIg Powder
1.3 Market Segment by Application
1.3.1 Global Human Immune Globulin Intravenous Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Immunodeficiency
1.3.3 Autoimmune Disease
1.3.4 Acute Infection
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Human Immune Globulin Intravenous Sales
2.1 Global Human Immune Globulin Intravenous Revenue Estimates and Forecasts 2018-2034
2.2 Global Human Immune Globulin Intravenous Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Human Immune Globulin Intravenous Revenue by Region
2.3.1 Global Human Immune Globulin Intravenous Revenue by Region (2018-2024)
2.3.2 Global Human Immune Globulin Intravenous Revenue by Region (2024-2034)
2.4 Global Human Immune Globulin Intravenous Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Human Immune Globulin Intravenous Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Human Immune Globulin Intravenous Sales Quantity by Region
2.6.1 Global Human Immune Globulin Intravenous Sales Quantity by Region (2018-2024)
2.6.2 Global Human Immune Globulin Intravenous Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Human Immune Globulin Intravenous Sales Quantity by Manufacturers
3.1.1 Global Human Immune Globulin Intravenous Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Human Immune Globulin Intravenous Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Human Immune Globulin Intravenous Sales in 2022
3.2 Global Human Immune Globulin Intravenous Revenue by Manufacturers
3.2.1 Global Human Immune Globulin Intravenous Revenue by Manufacturers (2018-2024)
3.2.2 Global Human Immune Globulin Intravenous Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Human Immune Globulin Intravenous Revenue in 2022
3.3 Global Human Immune Globulin Intravenous Sales Price by Manufacturers
3.4 Global Key Players of Human Immune Globulin Intravenous, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Human Immune Globulin Intravenous Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Human Immune Globulin Intravenous, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Human Immune Globulin Intravenous, Product Offered and Application
3.8 Global Key Manufacturers of Human Immune Globulin Intravenous, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Human Immune Globulin Intravenous Sales Quantity by Type
4.1.1 Global Human Immune Globulin Intravenous Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Human Immune Globulin Intravenous Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
4.2 Global Human Immune Globulin Intravenous Revenue by Type
4.2.1 Global Human Immune Globulin Intravenous Historical Revenue by Type (2018-2024)
4.2.2 Global Human Immune Globulin Intravenous Forecasted Revenue by Type (2024-2034)
4.2.3 Global Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
4.3 Global Human Immune Globulin Intravenous Price by Type
4.3.1 Global Human Immune Globulin Intravenous Price by Type (2018-2024)
4.3.2 Global Human Immune Globulin Intravenous Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Human Immune Globulin Intravenous Sales Quantity by Application
5.1.1 Global Human Immune Globulin Intravenous Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Human Immune Globulin Intravenous Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
5.2 Global Human Immune Globulin Intravenous Revenue by Application
5.2.1 Global Human Immune Globulin Intravenous Historical Revenue by Application (2018-2024)
5.2.2 Global Human Immune Globulin Intravenous Forecasted Revenue by Application (2024-2034)
5.2.3 Global Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
5.3 Global Human Immune Globulin Intravenous Price by Application
5.3.1 Global Human Immune Globulin Intravenous Price by Application (2018-2024)
5.3.2 Global Human Immune Globulin Intravenous Price Forecast by Application (2024-2034)
6 North America
6.1 North America Human Immune Globulin Intravenous Sales by Company
6.1.1 North America Human Immune Globulin Intravenous Revenue by Company (2018-2024)
6.1.2 North America Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024)
6.2 North America Human Immune Globulin Intravenous Market Size by Type
6.2.1 North America Human Immune Globulin Intravenous Sales Quantity by Type (2018-2034)
6.2.2 North America Human Immune Globulin Intravenous Revenue by Type (2018-2034)
6.3 North America Human Immune Globulin Intravenous Market Size by Application
6.3.1 North America Human Immune Globulin Intravenous Sales Quantity by Application (2018-2034)
6.3.2 North America Human Immune Globulin Intravenous Revenue by Application (2018-2034)
6.4 North America Human Immune Globulin Intravenous Market Size by Country
6.4.1 North America Human Immune Globulin Intravenous Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Human Immune Globulin Intravenous Revenue by Country (2018-2034)
6.4.3 North America Human Immune Globulin Intravenous Sales Quantity by Country (2018-2034)
6.4.4 the United States
6.4.5 Canada
7 Europe
7.1 Europe Human Immune Globulin Intravenous Sales by Company
7.1.1 Europe Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024)
7.1.2 Europe Human Immune Globulin Intravenous Revenue by Company (2018-2024)
7.2 Europe Human Immune Globulin Intravenous Market Size by Type
7.2.1 Europe Human Immune Globulin Intravenous Sales Quantity by Type (2018-2034)
7.2.2 Europe Human Immune Globulin Intravenous Revenue by Type (2018-2034)
7.3 Europe Human Immune Globulin Intravenous Market Size by Application
7.3.1 Europe Human Immune Globulin Intravenous Sales Quantity by Application (2018-2034)
7.3.2 Europe Human Immune Globulin Intravenous Revenue by Application (2018-2034)
7.4 Europe Human Immune Globulin Intravenous Market Size by Country
7.4.1 Europe Human Immune Globulin Intravenous Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Human Immune Globulin Intravenous Revenue by Country (2018-2034)
7.4.3 Europe Human Immune Globulin Intravenous Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 UK
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Human Immune Globulin Intravenous Sales by Company
8.1.1 China Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024)
8.1.2 China Human Immune Globulin Intravenous Revenue by Company (2018-2024)
8.2 China Human Immune Globulin Intravenous Market Size by Type
8.2.1 China Human Immune Globulin Intravenous Sales Quantity by Type (2018-2034)
8.2.2 China Human Immune Globulin Intravenous Revenue by Type (2018-2034)
8.3 China Human Immune Globulin Intravenous Market Size by Application
8.3.1 China Human Immune Globulin Intravenous Sales Quantity by Application (2018-2034)
8.3.2 China Human Immune Globulin Intravenous Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Human Immune Globulin Intravenous Sales by Company
9.1.1 APAC Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024)
9.1.2 APAC Human Immune Globulin Intravenous Revenue by Company (2018-2024)
9.2 APAC Human Immune Globulin Intravenous Market Size by Type
9.2.1 APAC Human Immune Globulin Intravenous Sales Quantity by Type (2018-2034)
9.2.2 APAC Human Immune Globulin Intravenous Revenue by Type (2018-2034)
9.3 APAC Human Immune Globulin Intravenous Market Size by Application
9.3.1 APAC Human Immune Globulin Intravenous Sales Quantity by Application (2018-2034)
9.3.2 APAC Human Immune Globulin Intravenous Revenue by Application (2018-2034)
9.4 APAC Human Immune Globulin Intravenous Market Size by Region
9.4.1 APAC Human Immune Globulin Intravenous Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Human Immune Globulin Intravenous Revenue by Region (2018-2034)
9.4.3 APAC Human Immune Globulin Intravenous Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales by Company
10.1.1 Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Human Immune Globulin Intravenous Market Size by Type
10.2.1 Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Human Immune Globulin Intravenous Market Size by Application
10.3.1 Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Human Immune Globulin Intravenous Market Size by Country
10.4.1 Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Overview
11.1.3 Takeda Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Takeda Human Immune Globulin Intravenous Products and Services
11.1.5 Takeda Human Immune Globulin Intravenous SWOT Analysis
11.1.6 Takeda Recent Developments
11.2 Grifols
11.2.1 Grifols Company Information
11.2.2 Grifols Overview
11.2.3 Grifols Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Grifols Human Immune Globulin Intravenous Products and Services
11.2.5 Grifols Human Immune Globulin Intravenous SWOT Analysis
11.2.6 Grifols Recent Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Overview
11.3.3 CSL Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 CSL Human Immune Globulin Intravenous Products and Services
11.3.5 CSL Human Immune Globulin Intravenous SWOT Analysis
11.3.6 CSL Recent Developments
11.4 Octapharma
11.4.1 Octapharma Company Information
11.4.2 Octapharma Overview
11.4.3 Octapharma Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Octapharma Human Immune Globulin Intravenous Products and Services
11.4.5 Octapharma Human Immune Globulin Intravenous SWOT Analysis
11.4.6 Octapharma Recent Developments
11.5 Biotest
11.5.1 Biotest Company Information
11.5.2 Biotest Overview
11.5.3 Biotest Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Biotest Human Immune Globulin Intravenous Products and Services
11.5.5 Biotest Human Immune Globulin Intravenous SWOT Analysis
11.5.6 Biotest Recent Developments
11.6 Kedrion
11.6.1 Kedrion Company Information
11.6.2 Kedrion Overview
11.6.3 Kedrion Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Kedrion Human Immune Globulin Intravenous Products and Services
11.6.5 Kedrion Human Immune Globulin Intravenous SWOT Analysis
11.6.6 Kedrion Recent Developments
11.7 Hualan Bio
11.7.1 Hualan Bio Company Information
11.7.2 Hualan Bio Overview
11.7.3 Hualan Bio Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Hualan Bio Human Immune Globulin Intravenous Products and Services
11.7.5 Hualan Bio Human Immune Globulin Intravenous SWOT Analysis
11.7.6 Hualan Bio Recent Developments
11.8 CNBG
11.8.1 CNBG Company Information
11.8.2 CNBG Overview
11.8.3 CNBG Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 CNBG Human Immune Globulin Intravenous Products and Services
11.8.5 CNBG Human Immune Globulin Intravenous SWOT Analysis
11.8.6 CNBG Recent Developments
11.9 Shanghai RAAS
11.9.1 Shanghai RAAS Company Information
11.9.2 Shanghai RAAS Overview
11.9.3 Shanghai RAAS Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Shanghai RAAS Human Immune Globulin Intravenous Products and Services
11.9.5 Shanghai RAAS Human Immune Globulin Intravenous SWOT Analysis
11.9.6 Shanghai RAAS Recent Developments
11.10 CBPO
11.10.1 CBPO Company Information
11.10.2 CBPO Overview
11.10.3 CBPO Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 CBPO Human Immune Globulin Intravenous Products and Services
11.10.5 CBPO Human Immune Globulin Intravenous SWOT Analysis
11.10.6 CBPO Recent Developments
11.11 LFB Group
11.11.1 LFB Group Company Information
11.11.2 LFB Group Overview
11.11.3 LFB Group Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 LFB Group Human Immune Globulin Intravenous Products and Services
11.11.5 LFB Group Recent Developments
11.12 BPL
11.12.1 BPL Company Information
11.12.2 BPL Overview
11.12.3 BPL Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 BPL Human Immune Globulin Intravenous Products and Services
11.12.5 BPL Recent Developments
11.13 Sichuan Yuanda Shuyang
11.13.1 Sichuan Yuanda Shuyang Company Information
11.13.2 Sichuan Yuanda Shuyang Overview
11.13.3 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Products and Services
11.13.5 Sichuan Yuanda Shuyang Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Human Immune Globulin Intravenous Value Chain Analysis
12.2 Human Immune Globulin Intravenous Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Human Immune Globulin Intravenous Production Mode & Process
12.4 Human Immune Globulin Intravenous Sales and Marketing
12.4.1 Human Immune Globulin Intravenous Sales Channels
12.4.2 Human Immune Globulin Intravenous Distributors
12.5 Human Immune Globulin Intravenous Customers
13 Market Dynamics
13.1 Human Immune Globulin Intravenous Industry Trends
13.2 Human Immune Globulin Intravenous Market Drivers
13.3 Human Immune Globulin Intravenous Market Challenges
13.4 Human Immune Globulin Intravenous Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Human Immune Globulin Intravenous Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of IVIg Liquid
Table 3. Major Manufacturers of IVIg Powder
Table 4. Global Human Immune Globulin Intravenous Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Human Immune Globulin Intravenous Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Human Immune Globulin Intravenous Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Human Immune Globulin Intravenous Revenue Market Share by Region (2018-2024)
Table 8. Global Human Immune Globulin Intravenous Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Human Immune Globulin Intravenous Revenue Market Share by Region (2024-2034)
Table 10. Global Human Immune Globulin Intravenous Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Human Immune Globulin Intravenous Sales by Region (2018-2024) & (K Units)
Table 12. Global Human Immune Globulin Intravenous Sales Market Share by Region (2018-2024)
Table 13. Global Human Immune Globulin Intravenous Sales by Region (2024-2034) & (K Units)
Table 14. Global Human Immune Globulin Intravenous Sales Market Share by Region (2024-2034)
Table 15. Global Human Immune Globulin Intravenous Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Human Immune Globulin Intravenous Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Human Immune Globulin Intravenous Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Human Immune Globulin Intravenous Revenue Share by Manufacturers (2018-2024)
Table 19. Global Human Immune Globulin Intravenous Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Human Immune Globulin Intravenous, Industry Ranking, 2021 VS 2022
Table 21. Global Human Immune Globulin Intravenous Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Human Immune Globulin Intravenous by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immune Globulin Intravenous as of 2022)
Table 23. Global Key Manufacturers of Human Immune Globulin Intravenous, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Human Immune Globulin Intravenous, Product Offered and Application
Table 25. Global Key Manufacturers of Human Immune Globulin Intravenous, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Human Immune Globulin Intravenous Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Human Immune Globulin Intravenous Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Human Immune Globulin Intravenous Sales Quantity Share by Type (2018-2024)
Table 30. Global Human Immune Globulin Intravenous Sales Quantity Share by Type (2024-2034)
Table 31. Global Human Immune Globulin Intravenous Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Human Immune Globulin Intravenous Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Human Immune Globulin Intravenous Revenue Share by Type (2018-2024)
Table 34. Global Human Immune Globulin Intravenous Revenue Share by Type (2024-2034)
Table 35. Human Immune Globulin Intravenous Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Human Immune Globulin Intravenous Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Human Immune Globulin Intravenous Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Human Immune Globulin Intravenous Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Human Immune Globulin Intravenous Sales Quantity Share by Application (2018-2024)
Table 40. Global Human Immune Globulin Intravenous Sales Quantity Share by Application (2024-2034)
Table 41. Global Human Immune Globulin Intravenous Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Human Immune Globulin Intravenous Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Human Immune Globulin Intravenous Revenue Share by Application (2018-2024)
Table 44. Global Human Immune Globulin Intravenous Revenue Share by Application (2024-2034)
Table 45. Human Immune Globulin Intravenous Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Human Immune Globulin Intravenous Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Human Immune Globulin Intravenous Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Human Immune Globulin Intravenous Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Human Immune Globulin Intravenous Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Human Immune Globulin Intravenous Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Human Immune Globulin Intravenous Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Human Immune Globulin Intravenous Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Human Immune Globulin Intravenous Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Human Immune Globulin Intravenous Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Human Immune Globulin Intravenous Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Human Immune Globulin Intravenous Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Human Immune Globulin Intravenous Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Human Immune Globulin Intravenous Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Human Immune Globulin Intravenous Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Human Immune Globulin Intravenous Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Human Immune Globulin Intravenous Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Human Immune Globulin Intravenous Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Human Immune Globulin Intravenous Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Human Immune Globulin Intravenous Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Human Immune Globulin Intravenous Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Human Immune Globulin Intravenous Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Human Immune Globulin Intravenous Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Human Immune Globulin Intravenous Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Human Immune Globulin Intravenous Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Human Immune Globulin Intravenous Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Human Immune Globulin Intravenous Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Human Immune Globulin Intravenous Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Human Immune Globulin Intravenous Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Human Immune Globulin Intravenous Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Human Immune Globulin Intravenous Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Human Immune Globulin Intravenous Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Human Immune Globulin Intravenous Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Human Immune Globulin Intravenous Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Human Immune Globulin Intravenous Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Human Immune Globulin Intravenous Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Human Immune Globulin Intravenous Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Human Immune Globulin Intravenous Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Human Immune Globulin Intravenous Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Human Immune Globulin Intravenous Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Human Immune Globulin Intravenous Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Human Immune Globulin Intravenous Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Human Immune Globulin Intravenous Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Human Immune Globulin Intravenous Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Human Immune Globulin Intravenous Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Human Immune Globulin Intravenous Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Human Immune Globulin Intravenous Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Human Immune Globulin Intravenous Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Human Immune Globulin Intravenous Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Human Immune Globulin Intravenous Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Human Immune Globulin Intravenous Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Human Immune Globulin Intravenous Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Human Immune Globulin Intravenous Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Takeda Company Information
Table 118. Takeda Description and Overview
Table 119. Takeda Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Takeda Human Immune Globulin Intravenous Product and Services
Table 121. Takeda Human Immune Globulin Intravenous SWOT Analysis
Table 122. Takeda Recent Developments
Table 123. Grifols Company Information
Table 124. Grifols Description and Overview
Table 125. Grifols Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. Grifols Human Immune Globulin Intravenous Product and Services
Table 127. Grifols Human Immune Globulin Intravenous SWOT Analysis
Table 128. Grifols Recent Developments
Table 129. CSL Company Information
Table 130. CSL Description and Overview
Table 131. CSL Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. CSL Human Immune Globulin Intravenous Product and Services
Table 133. CSL Human Immune Globulin Intravenous SWOT Analysis
Table 134. CSL Recent Developments
Table 135. Octapharma Company Information
Table 136. Octapharma Description and Overview
Table 137. Octapharma Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. Octapharma Human Immune Globulin Intravenous Product and Services
Table 139. Octapharma Human Immune Globulin Intravenous SWOT Analysis
Table 140. Octapharma Recent Developments
Table 141. Biotest Company Information
Table 142. Biotest Description and Overview
Table 143. Biotest Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 144. Biotest Human Immune Globulin Intravenous Product and Services
Table 145. Biotest Human Immune Globulin Intravenous SWOT Analysis
Table 146. Biotest Recent Developments
Table 147. Kedrion Company Information
Table 148. Kedrion Description and Overview
Table 149. Kedrion Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 150. Kedrion Human Immune Globulin Intravenous Product and Services
Table 151. Kedrion Human Immune Globulin Intravenous SWOT Analysis
Table 152. Kedrion Recent Developments
Table 153. Hualan Bio Company Information
Table 154. Hualan Bio Description and Overview
Table 155. Hualan Bio Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 156. Hualan Bio Human Immune Globulin Intravenous Product and Services
Table 157. Hualan Bio Human Immune Globulin Intravenous SWOT Analysis
Table 158. Hualan Bio Recent Developments
Table 159. CNBG Company Information
Table 160. CNBG Description and Overview
Table 161. CNBG Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 162. CNBG Human Immune Globulin Intravenous Product and Services
Table 163. CNBG Human Immune Globulin Intravenous SWOT Analysis
Table 164. CNBG Recent Developments
Table 165. Shanghai RAAS Company Information
Table 166. Shanghai RAAS Description and Overview
Table 167. Shanghai RAAS Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 168. Shanghai RAAS Human Immune Globulin Intravenous Product and Services
Table 169. Shanghai RAAS Human Immune Globulin Intravenous SWOT Analysis
Table 170. Shanghai RAAS Recent Developments
Table 171. CBPO Company Information
Table 172. CBPO Description and Overview
Table 173. CBPO Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 174. CBPO Human Immune Globulin Intravenous Product and Services
Table 175. CBPO Human Immune Globulin Intravenous SWOT Analysis
Table 176. CBPO Recent Developments
Table 177. LFB Group Company Information
Table 178. LFB Group Description and Overview
Table 179. LFB Group Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 180. LFB Group Human Immune Globulin Intravenous Product and Services
Table 181. LFB Group Recent Developments
Table 182. BPL Company Information
Table 183. BPL Description and Overview
Table 184. BPL Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 185. BPL Human Immune Globulin Intravenous Product and Services
Table 186. BPL Recent Developments
Table 187. Sichuan Yuanda Shuyang Company Information
Table 188. Sichuan Yuanda Shuyang Description and Overview
Table 189. Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 190. Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Product and Services
Table 191. Sichuan Yuanda Shuyang Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Human Immune Globulin Intravenous Distributors List
Table 195. Human Immune Globulin Intravenous Customers List
Table 196. Human Immune Globulin Intravenous Market Trends
Table 197. Human Immune Globulin Intravenous Market Drivers
Table 198. Human Immune Globulin Intravenous Market Challenges
Table 199. Human Immune Globulin Intravenous Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Human Immune Globulin Intravenous Product Picture
Figure 2. Global Human Immune Globulin Intravenous Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Human Immune Globulin Intravenous Market Share by Type in 2022 & 2034
Figure 4. IVIg Liquid Product Picture
Figure 5. IVIg Powder Product Picture
Figure 6. Global Human Immune Globulin Intravenous Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Human Immune Globulin Intravenous Market Share by Application in 2022 & 2034
Figure 8. Immunodeficiency
Figure 9. Autoimmune Disease
Figure 10. Acute Infection
Figure 11. Human Immune Globulin Intravenous Report Years Considered
Figure 12. Global Human Immune Globulin Intravenous Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Human Immune Globulin Intravenous Revenue 2018-2034 (US$ Million)
Figure 14. Global Human Immune Globulin Intravenous Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Human Immune Globulin Intravenous Sales Quantity 2018-2034 (K Units)
Figure 16. Global Human Immune Globulin Intravenous Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Human Immune Globulin Intravenous Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Human Immune Globulin Intravenous Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Human Immune Globulin Intravenous Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Human Immune Globulin Intravenous Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Human Immune Globulin Intravenous Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Human Immune Globulin Intravenous Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Human Immune Globulin Intravenous Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Human Immune Globulin Intravenous Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Human Immune Globulin Intravenous Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Human Immune Globulin Intravenous Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Human Immune Globulin Intravenous Revenue in 2022
Figure 30. Human Immune Globulin Intravenous Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
Figure 33. Global Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
Figure 35. North America Human Immune Globulin Intravenous Revenue Market Share by Company in 2022
Figure 36. North America Human Immune Globulin Intravenous Sales Quantity Market Share by Company in 2022
Figure 37. North America Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
Figure 39. North America Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
Figure 41. North America Human Immune Globulin Intravenous Revenue Share by Country (2018-2034)
Figure 42. North America Human Immune Globulin Intravenous Sales Quantity Share by Country (2018-2034)
Figure 43. the United States Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Human Immune Globulin Intravenous Sales Quantity Market Share by Company in 2022
Figure 46. Europe Human Immune Globulin Intravenous Revenue Market Share by Company in 2022
Figure 47. Europe Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
Figure 49. Europe Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
Figure 51. Europe Human Immune Globulin Intravenous Revenue Share by Country (2018-2034)
Figure 52. Europe Human Immune Globulin Intravenous Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 54. France Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 55. UK Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 58. China Human Immune Globulin Intravenous Sales Quantity Market Share by Company in 2022
Figure 59. China Human Immune Globulin Intravenous Revenue Market Share by Company in 2022
Figure 60. China Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
Figure 62. China Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
Figure 64. APAC Human Immune Globulin Intravenous Sales Quantity Market Share by Company in 2022
Figure 65. APAC Human Immune Globulin Intravenous Revenue Market Share by Company in 2022
Figure 66. APAC Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
Figure 68. APAC Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
Figure 70. APAC Human Immune Globulin Intravenous Revenue Share by Region (2018-2034)
Figure 71. APAC Human Immune Globulin Intravenous Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 76. India Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Human Immune Globulin Intravenous Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Human Immune Globulin Intravenous Revenue Share by Country (2018-2034)
Figure 85. Brazil Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Human Immune Globulin Intravenous Revenue (2018-2034) & (US$ Million)
Figure 90. Human Immune Globulin Intravenous Value Chain
Figure 91. Human Immune Globulin Intravenous Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed